Trial Profile

A phase II study assessing SCO-101 in combination paclitaxel in patients with metastatic drug-resistant breast cancer

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 30 May 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Paclitaxel (Primary) ; Endovion
Indications Advanced breast cancer
Focus Adverse reactions; Proof of concept; Therapeutic Use

Most Recent Events

30 May 2019 New trial record
27 May 2019 According to a Scandion Oncology media release, the first breast cancer patient is expected to be treated with SCO-101 and paclitaxel in Q2, 2020 and results will be available in Q2, 2021.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com